Gadoxetate Disodium Alert: Understanding Breathing Changes in Medical Imaging
"A Deep Dive into How Contrast Agents Affect Respiratory Function During Liver MRI Scans"
Gadoxetate disodium is a contrast agent frequently utilized in liver-specific magnetic resonance imaging (MRI), a vital tool for diagnosing focal liver lesions. Its primary advantage lies in enabling both dynamic contrast-enhanced imaging and hepatobiliary phase imaging within a clinically feasible timeframe, offering additional insights compared to conventional extracellular gadolinium agents.
However, the use of gadoxetate disodium has been associated with a phenomenon known as "severe respiratory motion artifact," often observed as suboptimal image quality during arterial phase imaging. This artifact was initially attributed to acute self-limiting dyspnea, suggesting that the respiratory effects of gadoxetate disodium could negatively impact the quality of arterial images. Subsequent research has focused on understanding the relationship between this artifact and the administration of gadoxetate disodium.
To directly investigate the respiratory effects of gadoxetate disodium, a study was conducted on mice to monitor their vital signs following the administration of contrast agents. This research aimed to provide a clearer understanding of how gadoxetate disodium affects respiratory function, independent of other potential factors influencing human subjects.
Breathing Changes and Imaging Timing
A study comparing gadoxetate disodium with gadoterate meglumine found that the transient respiratory anomaly occurred, on average, 11 seconds before arterial-phase imaging began with gadoterate. With gadoxetate, the anomaly occurred concurrently with the start of arterial-phase imaging, potentially affecting that imaging window. Separately, a 2015 report noted that safety data from routine clinical use of gadoxetate had not yet been reported when it described six multicenter studies assessing its safety profile.
Liver Assessment and MRI Protocols
For diagnosing liver fibrosis, liver biopsy is described as the reference-standard technique, but it is invasive, can be affected by sampling error from small tissue samples, and carries a risk of complications. Non-invasive alternatives include direct and indirect serum markers, serum panels, and imaging techniques. Gadoxetate-enhanced MRI literature also describes workflow-optimized pulse-sequence protocols and imaging appearances of focal lesions in noncirrhotic and cirrhotic livers.
Dual-Phase Liver Imaging
Gadoxetate disodium, also called Gd-EOB-DTPA, is described as a gadolinium-based contrast agent with dual-phase properties. It first distributes extracellularly and is then taken up and excreted by hepatocytes, enabling assessment of liver morphology and function. A 2023 review notes that gadoxetic acid-enhanced MRI shows liver-lesion enhancement in the dynamic phase, improves detection and characterization of hepatobiliary lesions, and provides qualitative and quantitative information about liver function and the biliary tract.
What the Mouse Study Revealed About Gadoxetate Disodium and Breathing
The study involved injecting mice with gadoxetate disodium and monitoring their respiratory rate (RR), peripheral oxygen saturation (SpO2), and heart rate. The findings indicated that gadoxetate disodium caused a rapid increase in respiratory rate (tachypnea) without significantly affecting oxygen saturation or heart rate. This effect was consistent regardless of the dilution method used.
- Tachypnea Induction: Gadoxetate disodium consistently caused a rapid increase in respiratory rate in mice.
- Oxygen Saturation: No significant changes in oxygen saturation were observed, indicating that the tachypnea did not compromise oxygen levels.
- Heart Rate Stability: Heart rate remained relatively stable, suggesting that the respiratory effects were not linked to cardiac changes.
- Comparison with Other Agents: Gadoxetate disodium had a more significant impact on respiratory rate compared to gadoteridol and gadopentetate dimeglumine.
Harmonizing Quantitative Liver Function Measures
A study published in 2025 set out to develop a clinically applicable harmonization method for the hepatocellular uptake index (HUI), a quantitative liver-function index measured using gadoxetate disodium-enhanced MRI. Its stated aim is to improve consistency across diverse MR systems. The supplied study description identifies the work as retrospective and says it included consecutive patients who underwent the imaging, but provides no results.
Motion Artifacts and Remaining Limitations
A study of shortened and multiple arterial-phase acquisitions reported that scan timing could still be inadequate in 2.0% of cases (5 of 250), even with multiple arterial-phase acquisition. Another study noted that its retrospective design prevented assessment of self-reported dyspnea during contrast injection, which is associated to some degree with severe respiratory-motion artifact but is not necessarily linked to it in every case. These findings highlight limitations in timing and in establishing the relationship between reported breathing symptoms and imaging artifacts.
Reported Motion and Dyspnea Rates
A systematic review and meta-analysis found that studies using single arterial-phase imaging reported transient severe motion (TSM) rates ranging from 4.8% to 26.7%; the pooled incidence was 13.0% (95% CI, 10.3%–16.2%), with substantial study heterogeneity. In a separate comparison, acute transient dyspnea complaints were more frequent after gadoxetate disodium than after gadobenate dimeglumine: 14% (14 of 99) versus 5% (5 of 99), respectively (P = .05). These figures describe different outcomes and study comparisons, so they should not be treated as interchangeable rates.
What This Means for Patients and Future Research
The study's findings provide valuable insights for radiologists and healthcare professionals using gadoxetate disodium in liver MRI. Understanding the potential for tachypnea can aid in optimizing imaging protocols and patient monitoring to minimize respiratory motion artifacts and ensure image quality. While the study focused on mice, the results underscore the importance of considering respiratory effects when administering gadoxetate disodium to human patients.
Market Forecast and Noninvasive Function Assessment
One market report projects the gadoxetate disodium market at $1.42 billion by 2030 and identifies multi-organ imaging and pre-surgical evaluation applications as key growth drivers. Separately, Antaros Medical describes using gadoxetate imaging to non-invasively assess liver function in clinical trials. Its overview notes that chronic liver disease can involve decreased hepatic function resulting from inflammation, cholestasis, and/or fibrosis, and that diagnosis, severity staging, and treatment-response assessment are often done via liver biopsy.